Hjem › Ægstockræft › Oklahoma
Ægstockræft kliniske forsøg i Oklahoma
31 studier for Ægstockræft søger deltagere på steder i Oklahoma.
Byer i Oklahoma
Officiel studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alle aldre · Alle køn · Opdateret 2. okt. 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 1. okt. 2026 · NCT07024784Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Stephenson Cancer Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Kvinder · Opdateret 25. sep. 2026 · NCT03564340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007), Tulsa
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 17. sep. 2026 · NCT07318558Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- OU Health, Stephenson Cancer Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Kvinder · Opdateret 15. sep. 2026 · NCT05739981FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06303505A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 3. sep. 2026 · NCT06824467The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFrivillige med god helbredstilstand velkomne
Alder 45 til 75 · Alle køn · Opdateret 2. sep. 2026 · NCT06995898Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 26. aug. 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 1
Alder 15 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT06276491A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT07182149A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT06751329A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Rekrutterer
Alder 35 til 50 · Kvinder · Opdateret 7. aug. 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT04657068Clinical Pre-screening Protocol for Ovarian Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererObservationsstudie
Alder 18 og opefter · Kvinder · Opdateret 30. jul. 2026 · NCT03877796A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 28. jul. 2026 · NCT06161025Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Oklahoma, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 14. jul. 2026 · NCT04606914A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. jul. 2026 · NCT04389632A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT05377996Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFrivillige med god helbredstilstand velkomne
Alder 50 til 74 · Kvinder · Opdateret 6. maj 2026 · NCT00539162A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 14. jan. 2026 · NCT06234423A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 7. jan. 2026 · NCT06999187CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 23. dec. 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. sep. 2025 · NCT05932862Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.